Widening eligibility to phase II trials: constant arcsine difference phase II trialsA'HERN, Roger P.Controlled clinical trials. 2004, Vol 25, Num 3, pp 251-264, issn 0197-2456, 14 p.Article

A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-lnduced neuromuscular blockGROUDINE, Scott B; SOTO, Roy; LIEN, Cynthia et al.Anesthesia and analgesia. 2007, Vol 104, Num 3, pp 555-562, issn 0003-2999, 8 p.Article

Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas = Essai phase II et pharmacocinétique de l'aziridinylbenzoquinone [2,5-dioziridinyl-3,6-bis(carboéthoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] dans les gliomes de grade élevéCURT, G. A; KELLEY, J. A; KUFTA, C. V et al.Cancer research (Baltimore). 1983, Vol 43, Num 12, pp 6102-6105, issn 0008-5472Article

An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced ParkinsonismPERENYI, A; BAGDY, G; ARATO, M et al.Pharmacopsychiatria. 1983, Vol 16, Num 5, pp 143-146, issn 0720-4280Article

Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpointsCAPRA, William B.Controlled clinical trials. 2004, Vol 25, Num 2, pp 168-177, issn 0197-2456, 10 p.Article

The unclear zone in phase II clinical trialsALLEGRO, Sabrina; POND, Gregory R; HOTTE, Sébastien J et al.European journal of cancer (1990). 2010, Vol 46, Num 13, pp 2408-2413, issn 0959-8049, 6 p.Article

Multiple Histology Phase II TrialsLEBLANC, Michael; RANKIN, Cathryn; CROWLEY, John et al.Clinical cancer research (Print). 2009, Vol 15, Num 13, pp 4256-4262, issn 1078-0432, 7 p.Article

Differential Roles of Phase I and Phase II Enzymes in 3,4-Methylendioxymethamphetamine-Induced CytotoxicityANTOLINO-LOBO, Irene; MEULENBELT, Jan; NIJMEIJER, Sandra M et al.Drug metabolism and disposition. 2010, Vol 38, Num 7, pp 1105-1112, issn 0090-9556, 8 p.Article

Novel Designs and End Points for Phase II Clinical Trials : Phase II Trials: Designs for the futureADJEI, Alex A; CHRISTIAN, Michaele; IVY, Percy et al.Clinical cancer research (Print). 2009, Vol 15, Num 6, pp 1866-1872, issn 1078-0432, 7 p.Article

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALSLEVY, G; KAUFMANN, P; THOMPSON, J. L. P et al.Neurology. 2006, Vol 66, Num 5, pp 660-663, issn 0028-3878, 4 p.Article

Randomized phase II clinical trialsSIMON, R; WITTES, R. E; ELLENBERG, S. S et al.Cancer treatment reports. 1985, Vol 69, Num 12, pp 1375-1381, issn 0361-5960Article

Clinical drug development: an analysis of phase II trials, 1970-1985MARSONI, S; HOTH, D; SIMON, R et al.Cancer treatment reports. 1987, Vol 71, Num 1, pp 71-80, issn 0361-5960Article

A three-outcome design for phase II clinical trialsSARGENT, Daniel J; CHAN, Victor; GOLDBERG, Richard M et al.Controlled clinical trials. 2001, Vol 22, Num 2, pp 117-125, issn 0197-2456Article

CLINICAL STUDIES. V: RATIONALE, DESIGN, AND METHODOLOGY OF PHASE II CLINICAL TRIALSMUGOIA FM; MCGUIRE WP; PROZENCWEIG M et al.1979; METHODS CANCER RES.; USA; DA. 1979; VOL. 17; PP. 199-214; BIBL. 2 P.Article

ONE-SAMPLE MULTIPLE TESTING PROCEDURE FOR PHASE II CLINICAL TRIALSFLEMING TR.1982; BIOMETRICS; ISSN 0006-341X; USA; DA. 1982; VOL. 38; NO 1; PP. 143-151; ABS. FRE; BIBL. 11 REF.Article

Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal CancerMABRO, May; LOUVET, Christophe; ANDRE, Thierry et al.American journal of clinical oncology. 2003, Vol 26, Num 3, pp 254-258, issn 0277-3732, 5 p.Article

Clinical development of dietary supplements: The perils of starting at phase IIIBERMAN, Josh.Fitoterapia (Milano). 2011, Vol 82, Num 1, pp 80-84, issn 0367-326X, 5 p.Article

Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaeniaFRAKKING, Florine N. J; BROUWER, Nannette; KUIJPERS, Taco W et al.European journal of cancer (1990). 2009, Vol 45, Num 4, pp 505-512, issn 0959-8049, 8 p.Article

Improving the design of phase II trials of cytostatic anticancer agentsSTONE, Andrew; WHEELER, Catherine; BARGE, Alan et al.Contemporary clinical trials. 2007, Vol 28, Num 2, pp 138-145, issn 1551-7144, 8 p.Article

A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: A Southwest Oncology Group StudyWHITEHEAD, Robert P; MOON, James; MCCACHREN, S. Spence et al.Cancer. 2004, Vol 100, Num 8, pp 1699-1704, issn 0008-543X, 6 p.Article

Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trialRENI, Michele; MASON, Warren; PACE, Andrea et al.European journal of cancer (1990). 2004, Vol 40, Num 11, pp 1682-1688, issn 0959-8049, 7 p.Article

Acceptability and adherence: findings from a Phase II study of a candidate vaginal microbicide, 'Praneem polyherbal tablet', in Pune, IndiaJOGLEKAR, N. S; JOSHI, S. N; DESHPANDE, S. S et al.Transactions of the Royal Society of Tropical Medicine and Hygiene. 2010, Vol 104, Num 6, pp 412-415, issn 0035-9203, 4 p.Article

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcomaBAILEY, Howard H; MAHONEY, Michelle R; ETTINGER, David S et al.Cancer. 2006, Vol 107, Num 10, pp 2462-2467, issn 0008-543X, 6 p.Article

Samples of exact k-stage group sequential designs for Phase II and Pilot studiesKEPNER, James L; CHANG, Myron N.Controlled clinical trials. 2004, Vol 25, Num 3, pp 326-333, issn 0197-2456, 8 p.Article

THE MEASUREMENT OF THERAPEUTIC VALUEWARDELL WM; DIRADDO J; WEINTRAUB M et al.1980; J. CLIN. PHARMACOL.; USA; DA. 1980; VOL. 20; NO 2-3; PP. 77-90; BIBL. 32 REF.Article